Variations in the TSPO neuroinflammation-associated protein's structure correlates with worse survival outcomes for male glioblastoma brain cancer patients than females.
A combination of approved and novel therapeutics improved survival rates and reduced both tumor volume and growth for those suffering from glioblastoma brain cancer.
Cellular reprogramming of glioma cells into neural cells may be a promising treatment for glioblastoma brain cancer.
Researchers have identified specific proteins that drive the development of cancer stem cells. They report targeting and suppressing galectin1, in addition to radiation therapy, could be an effective treatment for glioblastoma brain cancer.
Researchers have successfully replicated an entire, viable glioblastoma brain tumor via 3D bioprinting. The bioprinted tumor includes a complex system of blood vessel-like tubes through which blood cells and drug molecules can flow, simulating a real tumor.
A novel helmet that generates a noninvasive oscillating magnetic field was able to reduce tumor mass by 31% in a glioblastoma brain cancer patient.
Combining αGITR antibodies with ICBs resulted in stronger survival benefits in mouse models of human glioblastoma brain cancer.
Glioblastoma can mimic the normal repair of white matter in the brain, causing the tumor to become less malignant. Additionally, a drug commonly prescribed for asthma can help suppress glioblastoma growth in mouse models.